Drug intelligence / Profile preview

diphtheria, tetanus, pertussis (whole cell), hepatitis b and haemophilus influenzae type b vaccine

Development stage: Approved
Lead developer: Immunobiological Technology Institute (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz)
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The diphtheria-tetanus-pertussis whole-cell hepatitis B Hib vaccine is a pentavalent combination vaccine developed by Bio-Manguinhos/Fiocruz in partnership with Instituto Butantan for the Brazilian National Immunization Program. It provides active immunization against five major pediatric diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and infections caused by Haemophilus influenzae type b (Hib), such as meningitis and pneumonia. The vaccine formulation consists of diphtheria and tetanus toxoids, inactivated whole-cell Bordetella pertussis, recombinant hepatitis B surface antigen (HBsAg), and Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid (PRP-T). It is administered as an intramuscular suspension, typically in a three-dose primary series for infants at 2, 4, and 6 months of age. The Hib component technology was originally transferred to Bio-Manguinhos from GSK Biologicals.

Other names: Brazilian pentavalent vaccinevacina pentavalente (DTPw/HB/Hib)diphtheria-tetanus-pertussis whole-cell hepatitis B Hib vaccine

Targets

Diphtheria toxinPRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on diphtheria, tetanus, pertussis (whole cell), hepatitis b and haemophilus influenzae type b vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphtheria, tetanus, pertussis (whole cell), hepatitis b and haemophilus influenzae type b vaccine.

Explore the full profile